-
21.发明申请USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS 有权使用抗CGRP抗体和抗体片段，以防止或抑制需要的物质，特别是MIGRAINE SUFFERERS公开(公告)号：US20120294802A1
公开(公告)日：2012-11-22
申请号：US13476632
申请日：2012-05-21
申请人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T.L. Smith , Leon F. Garcia-Martinez
发明人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T.L. Smith , Leon F. Garcia-Martinez
IPC分类号： A61K39/395 , A61K51/10 , A61P25/06 , A61P25/00 , A61P27/02 , A61P27/12 , A61P13/00 , A61P35/00 , A61P31/16 , A61P31/04 , A61P3/00 , A61P31/12 , A61P25/24 , A61P25/04 , A61P29/00 , A61P37/08 , A61P15/00 , A61P19/10 , A61K49/00
CPC分类号： C07K16/18 , A61K2039/505 , Y02A50/383
摘要： The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
摘要翻译： 本发明涉及使用抗CGRP抗体或抑制畏光特别是CGRP相关畏光的抗体片段抑制或预防有需要的受试者的畏光的方法。 这些抗体和片段可用于治疗与畏光相关的不同疾病，例如偏头痛，丛集性头痛等。
-
公开(公告)号：US09775921B2
公开(公告)日：2017-10-03
申请号：US13511865
申请日：2010-11-24
申请人： Leon F. Garcia-Martinez , Anne Elisabeth Carvalho Jensen , Katie Anderson , Benjamin H. Dutzar , John A. Latham , Brian R. Kovacevich , Jeffrey T. L. Smith , Mark Litton , Randall Schatzman
发明人： Leon F. Garcia-Martinez , Anne Elisabeth Carvalho Jensen , Katie Anderson , Benjamin H. Dutzar , John A. Latham , Brian R. Kovacevich , Jeffrey T. L. Smith , Mark Litton , Randall Schatzman
CPC分类号： A61K51/1033 , A61K49/0004 , A61K49/0058 , A61K2039/505 , C07K16/248 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6863 , Y02A50/412 , Y02A50/58
摘要： The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.
-
公开(公告)号：US09708393B2
公开(公告)日：2017-07-18
申请号：US13476632
申请日：2012-05-21
申请人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T. L. Smith , Leon F. Garcia-Martinez
发明人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T. L. Smith , Leon F. Garcia-Martinez
IPC分类号： A61K39/395 , C07K16/18 , C07K16/44 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , Y02A50/383
摘要： The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.
-
公开(公告)号：US11214610B2
公开(公告)日：2022-01-04
申请号：US13466795
申请日：2012-05-08
申请人： Patricia Dianne McNeill , Leon F. Garcia-Martinez , Nicole Janson , Gary Lesnicki , Pei Qi , John A. Latham
发明人： Patricia Dianne McNeill , Leon F. Garcia-Martinez , Nicole Janson , Gary Lesnicki , Pei Qi , John A. Latham
摘要： Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
-
公开(公告)号：US09855332B2
公开(公告)日：2018-01-02
申请号：US13476104
申请日：2012-05-21
申请人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T. L. Smith , Leon F. Garcia-Martinez
发明人： Andrew F. Russo , Eric A. Kaiser , Ana Recober , Adisa Kuburas , Ann C. Raddant , Brian Robert Kovacevich , John A. Latham , Jeffrey T. L. Smith , Leon F. Garcia-Martinez
CPC分类号： A61K45/06 , A61K2039/505 , C07K16/26 , C07K2317/24 , C07K2317/76
摘要： The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
-
26.发明申请HIGH-PURITY PRODUCTION OF MULTI-SUBUNIT PROTEINS SUCH AS ANTIBODIES IN TRANSFORMED MICROBES SUCH AS PICHIA PASTORIS 审中-公开多亚型蛋白质的高纯度生产如转化微生物中的抗体如PICHIA PASTORIS公开(公告)号：US20120277408A1
公开(公告)日：2012-11-01
申请号：US13466795
申请日：2012-05-08
申请人： Patricia Dianne McNeill , Leon F. Garcia-Martinez , Nicole Janson , Gary Lesnicki , Pei Qi , John A. Latham
发明人： Patricia Dianne McNeill , Leon F. Garcia-Martinez , Nicole Janson , Gary Lesnicki , Pei Qi , John A. Latham
CPC分类号： C07K16/00 , C07K2317/14 , C12P21/00
摘要： Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
摘要翻译： 公开了在转化细胞中产生异源多亚基蛋白的方法。 特别地，本公开提供了产生多亚单位蛋白质的改进方法，所述多亚单位蛋白质包括抗体和其它多亚基蛋白质，其可以分泌或不分泌，具有更高的产量和减少不期望的副产物的产生。 在示例性实施方案中，转化的细胞是酵母，例如甲基营养酵母，例如巴斯德毕赤酵母。
-
27.发明申请ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE , AND/OR FEVER 有权IL-6的拮抗作用可以预防或治疗慢性病，脆弱性，疲劳和/或感染公开(公告)号：US20130183293A1
公开(公告)日：2013-07-18
申请号：US13681501
申请日：2012-11-20
IPC分类号： C07K16/24 , A61K39/395 , A61K45/06
CPC分类号： C07K16/248 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y02A50/412
摘要： The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
摘要翻译： 本发明涉及使用具有IL-6结合特异性的抗体及其片段以预防或治疗有需要的患者的恶病质，发热，乏力和/或疲劳的治疗方法。 在优选的实施方案中，抗IL-6抗体将被人源化和/或将被糖基化。 此外，在优选实施方案中，这些患者将包括显示升高的血清C-反应蛋白水平（或处于发展中的风险）的那些。 在另一个优选实施例中，优选地改善患者的生存性或生活质量。
-
28.发明申请ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE AND/OR FEVER 有权IL-6的拮抗作用可以预防或治疗慢性病，脆弱性，疲劳和/或感染公开(公告)号：US20130028860A1
公开(公告)日：2013-01-31
申请号：US13511385
申请日：2010-11-24
IPC分类号： A61K39/395 , A61P29/00 , A61P25/00 , A61K38/20 , A61P21/00
CPC分类号： A61K39/3955 , A61K31/454 , A61K38/2013 , A61K38/208 , A61K45/06 , A61K49/0004 , A61K49/0058 , A61K51/1033 , A61K2039/505 , A61K2039/545 , C07K16/248 , C07K16/462 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/6863 , Y02A50/412 , Y02A50/58
摘要： The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
摘要翻译： 本发明涉及使用具有IL-6结合特异性的抗体及其片段的治疗方法和组合物，特别是皮下和静脉内组合物，以预防或治疗有需要的患者的恶病质，发热，无力和/或疲劳。 在优选的实施方案中，抗IL-6抗体将被人源化和/或将被糖基化。 此外，在优选实施方案中，这些患者将包括显示升高的血清C-反应蛋白水平（或处于发展中的风险）的那些。 在另一个优选实施例中，优选地改善患者的生存性或生活质量。
-
公开(公告)号：US08992904B2
公开(公告)日：2015-03-31
申请号：US13511385
申请日：2010-11-24
IPC分类号： A61K39/395 , C07K16/24 , A61K38/20 , A61K31/454 , A61K39/00
摘要： The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
-
公开(公告)号：US09724410B2
公开(公告)日：2017-08-08
申请号：US13511385
申请日：2010-11-24
IPC分类号： A61K39/395 , C07K16/24 , A61K38/20 , A61K31/454 , A61K45/06 , C07K16/46 , A61K39/00
CPC分类号： A61K39/3955 , A61K31/454 , A61K38/2013 , A61K38/208 , A61K45/06 , A61K49/0004 , A61K49/0058 , A61K51/1033 , A61K2039/505 , A61K2039/545 , C07K16/248 , C07K16/462 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/6863 , Y02A50/412 , Y02A50/58
摘要： The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.046 秒)
